Previous 10 | Next 10 |
Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...
Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...
Ventyx Biosciences, Inc. (VTYX) Q2 2022 Earnings Conference Call August 15, 2022 16:30 ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers C...
Announcing initial data from a Phase 1 trial, the clinical-stage biopharma Ventyx Biosciences ( NASDAQ: VTYX ) said on Monday that its lead candidate VTX958 was well tolerated by 96 healthy adult volunteers who took part in the study. The two-part, randomized study consisted...
Ventyx Biosciences press release ( NASDAQ: VTYX ): Q2 GAAP EPS of -$0.39 beats by $0.06 . VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable ...
VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial Cash, cash equivalents and marketable securities of $258.4 million as of June 30, 2022, expected to support operations into the first half of 2024 ...
VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile Class-leading target coverage, with TYK2 IC 50 and IC 90 coverage up to 24 hours Robust dose-dependent pharmacodynamic activity and evidence of target engage...
ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need toda...
Gainers: Qudian ( QD ) +48% . Marathon Digital ( MARA ) +32% . SQL Technologies ( SKYX ) +27% . SOS ( SOS ) +25% . Hut 8 Mining ( HUT ) +24% . North European Oil Royalty Trust ( NRT ) +24% . Advent Technologies ( ...
VTX2735, a candidate from Ventyx Biosciences ( NASDAQ: VTYX ) for autoimmune and autoinflammatory conditions, met safety, tolerability, and pharmacokinetics goals in a phase 1 trial. The trial evaluated single ascending dose and multiple ascending doses. Drug-related ...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...